Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.65 USD | -5.53% | -0.05% | -15.85% |
May. 10 | Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027 | MT |
Apr. 30 | Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 1.36B |
---|---|---|---|---|---|
Net income 2024 * | -234M | Net income 2025 * | -270M | EV / Sales 2024 * | - |
Net cash position 2024 * | 508M | Net cash position 2025 * | 476M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.75
x | P/E ratio 2025 * |
-4.48
x | Employees | 56 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.59% |
Latest transcript on Akero Therapeutics, Inc.
1 day | -5.53% | ||
1 week | -0.05% | ||
Current month | -1.21% | ||
1 month | -11.41% | ||
3 months | -10.19% | ||
6 months | +38.77% | ||
Current year | -15.85% |
Managers | Title | Age | Since |
---|---|---|---|
Jonathan Young
FOU | Founder | 54 | 17-03-31 |
Timothy Rolph
FOU | Founder | 70 | 17-03-31 |
Andrew Cheng
CEO | Chief Executive Officer | 57 | 18-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Seth Harrison
BRD | Director/Board Member | 63 | 16-12-31 |
Jane Henderson
BRD | Director/Board Member | 58 | 19-04-22 |
Mark Iwicki
CHM | Chairman | 57 | 18-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.18% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | +2.72% | - | |
0.10% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 19.65 | -5.53% | 567,401 |
24-05-09 | 20.8 | -1.05% | 414,291 |
24-05-08 | 21.02 | -4.54% | 581,020 |
24-05-07 | 22.02 | -0.41% | 502,186 |
24-05-06 | 22.11 | +12.46% | 896,226 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.85% | 1.36B | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- AKRO Stock